Ultralife Q1 2024 Adj EPS $0.21 Beats $0.10 Estimate, Sales $41.927M Beat $38.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ultralife Corporation reported Q1 2024 adjusted EPS of $0.21, surpassing the $0.10 estimate, with sales of $41.927M exceeding the $38.000M forecast. This represents a 31.37% increase in sales compared to the same period last year.
April 25, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultralife Corporation exceeded Q1 2024 earnings and sales estimates, with a significant year-over-year sales increase.
Ultralife's substantial beat on both earnings per share and sales estimates, coupled with a significant year-over-year sales growth, indicates strong operational performance and market confidence. This is likely to positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100